These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7027062)

  • 1. 1-year controlled trial of 1 alpha-hydroxycholecalciferol in patients on maintenance hemodialysis.
    Shimamatsu K; Maeda T; Harada A; Nishitani H; Onoyama K; Fujimi S; Omae T
    Nephron; 1981; 28(2):70-5. PubMed ID: 7027062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.
    Berl T; Berns AS; Hufer WE; Hammill K; Alfrey AC; Arnaud CD; Schrier RW
    Ann Intern Med; 1978 Jun; 88(6):774-80. PubMed ID: 208439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH; Huang TS; Hsieh SJ
    Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.
    Brandi L; Daugaard H; Tvedegaard E; Storm T; Olgaard K
    Nephron; 1989; 53(3):194-200. PubMed ID: 2797340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; de Luca HF
    Proc Eur Dial Transplant Assoc; 1976; 12():227-36. PubMed ID: 935115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
    Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
    Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 24R,25-dihydroxyvitamin D3 in combination with 1 alpha-hydroxyvitamin D3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone.
    Birkenhäger-Frenkel DH; Pols HA; Zeelenberg J; Eijgelsheim JJ; Schot R; Nigg AL; Weimar W; Mulder PG; Birkenhäger JC
    J Bone Miner Res; 1995 Feb; 10(2):197-204. PubMed ID: 7754799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term treatment with large doses of alphacalicidol in secondary hyperparathyroidism of patients dialyzed for end stage renal failure].
    Matuszkiewicz-Rowińska J; Niemczyk S; Pacocha E; Puka J; Switalski M; Bogdańska-Straszyńska B; Ostrowski K
    Pol Arch Med Wewn; 1996 Jul; 96(1):15-22. PubMed ID: 8966141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of the treatment efficacy of secondary hyperparathyroidism with oral pulse doses of alphacalcidol].
    Switalski M; Kuriga M; Wańkowicz Z
    Pol Arch Med Wewn; 1997 Oct; 98(10):358-65. PubMed ID: 9557090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers.
    Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
    Nephrol Dial Transplant; 2008 Nov; 23(11):3670-6. PubMed ID: 18579534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biochemical changes in patients with chronic renal insufficiency during hemodialysis depending on whether or not they received 25-(OH)D3].
    Rico H; Naranjo P; Paniagua MC; Cordero M; Bordiu E; Charro A
    Rev Clin Esp; 1982 Oct; 167(1):45-7. PubMed ID: 7178586
    [No Abstract]   [Full Text] [Related]  

  • 14. [Renal osteodystrophy: the importance of 1-alpha-OH-D3].
    Berland Y; Olmer M; Grandvuillemin M; Lachaize AM
    Sem Hop; 1981 Mar 8-15; 57(9-10):445-9. PubMed ID: 6261385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1-alpha-hydroxycholecalciferol for renal osteodystrophy.
    Brownjohn AM; Goodwin FJ; Hately W; Marsh FP; O'Riordan JL; Papapoulos SE
    Br Med J; 1977 Sep; 2(6089):721-3. PubMed ID: 912269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute effect of oral, intraperitoneal, and intravenous 1 alpha-hydroxycholecalciferol on markers of bone metabolism.
    Joffe P; Ladefoged SD; Cintin C; Jensen LT; Hyldstrup L
    Nephrol Dial Transplant; 1994; 9(5):524-31. PubMed ID: 8090332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of reduced dialysate calcium on calcium-phosphorus product and bone metabolism in hemodialysis patients.
    Fiedler R; Deuber HJ; Langer T; Osten B; Mohan S; Jehle PM
    Nephron Clin Pract; 2004; 96(1):c3-9. PubMed ID: 14752247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 2 years' treatment of osteoporosis with 1 alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study.
    Shikari M; Kushida K; Yamazaki K; Nagai T; Inoue T; Orimo H
    Endocr J; 1996 Apr; 43(2):211-20. PubMed ID: 9026268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of 1 alpha-OH-D3 on the process of fracture healing (author's transl)].
    Tanaka J
    Nihon Seikeigeka Gakkai Zasshi; 1980 Aug; 54(8):749-65. PubMed ID: 7205041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis.
    Morinière P; Fournier A; Leflon A; Hervé M; Sebert JL; Grégoire I; Bataille P; Guéris J
    Nephron; 1985; 39(4):309-15. PubMed ID: 3982576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.